Wir sind mit live! Mehr erfahren

Amgen

AMGN

Börsenwert 234 Mrd. $

432,49 USD

-1,54

0,35 %

Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT

Vor Börsenbeginn

Nachbörslich

432,49

0,00

0 %

1 Tag

-0,35 %

5 Tage

3,93 %

1 Monat

14,92 %

3 Monate

16,39 %

6 Monate

23,78 %

Seit Jahresbeginn

32 %

1 Jahr

46,21 %

5 Jahre

112,91 %

10 Jahre

165,95 %

Profil: Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis, which has been further strengthened with the launch of new drugs in blood cancers (Blincyto) and solid tumors (Imdelltra). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Mitarbeiter: 31.500

Gesundheitswesen Arzneimittelhersteller – allgemein

Nachrichten

Positiv

Neutral

Negativ

Stimmung 3 Monate

Positiv 48,8 %

Neutral 30,9 %

Negativ 20,3 %

Investors Business Daily

9 Dow Jones Stocks Make Bullish Moves In A Defensive Market Rotation

A week that tested the financial markets showed the resilience of Dow Jones stocks. Apple and Coca-Cola were among nine standouts.

9 Dow Jones Stocks Make Bullish Moves In A Defensive Market Rotation

Zacks Investment Research

Amgen (AMGN) Exceeds Market Returns: Some Facts to Consider

The latest trading day saw Amgen (AMGN) settling at $434.03, representing a +1.86% change from its previous close.

Amgen (AMGN) Exceeds Market Returns: Some Facts to Consider

These Consumer Stocks Are Getting a Lift as Investors Rotate Out of Tech

Some beaten-down consumer names are getting a boost as investors pull back from tech stocks.

These Consumer Stocks Are Getting a Lift as Investors Rotate Out of Tech

Big pharma stocks near all-time highs as tech selloff pushes investors toward safer bets

Shares of AbbVie, Eli Lilly and Gilead Sciences are trading at or near record highs.

Big pharma stocks near all-time highs as tech selloff pushes investors toward safer bets

24/7 Wall Street

AMGN vs. MRK: Which Pharma Giant's Dividend Actually Has Room to Grow

Amgen and Merck both yield around 2.3% and have surged this year, but one of them is paying its dividend out of thin air while the other has a cash cushion that changes the entire income calculus.

AMGN vs. MRK: Which Pharma Giant's Dividend Actually Has Room to Grow

24/7 Wall Street

Blockbuster Drugs Come and Go. These 5 Pharma Dividend Stocks Keep Paying

Every big pharma company eventually watches its best-selling drug go generic, yet some keep raising their dividends anyway.

Blockbuster Drugs Come and Go. These 5 Pharma Dividend Stocks Keep Paying

Zacks Investment Research

Here's Why Amgen (AMGN) is a Strong Momentum Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Here's Why Amgen (AMGN) is a Strong Momentum Stock

Zacks Investment Research

Amgen (AMGN) Laps the Stock Market: Here's Why

In the closing of the recent trading day, Amgen (AMGN) stood at $414.87, denoting a +1.82% move from the preceding trading day.

Amgen (AMGN) Laps the Stock Market: Here's Why

The Motley Fool

A Stock Market Crash Is Coming By the End of 2027, According to Some Economists. Here Are 2 Stocks to Buy Before That Happens

AbbVie has a diversified portfolio of drugs and a deep pipeline that could help it overcome patent cliffs. Amgen has navigated previous market crashes rather well, and it still appears relatively well-equipped to do so.

A Stock Market Crash Is Coming By the End of 2027, According to Some Economists. Here Are 2 Stocks to Buy Before That Happens

Zacks Investment Research

Amgen (AMGN) Advances While Market Declines: Some Information for Investors

In the closing of the recent trading day, Amgen (AMGN) stood at $413.08, denoting a +2.6% move from the preceding trading day.

Amgen (AMGN) Advances While Market Declines: Some Information for Investors

Nachrichtenrankings ansehen

Kursdiagramme mit Lightweight Charts™ umgesetzt